PODESTA GROUP, INC. for MILLENNIUM PHARMACEUTICALS INC
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
FY 2013 budget resolutions. H. Con. Res 112, Establishing the budget for the US Government for FY 2013. H.R. 5973 / S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013.
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millennium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
Pharmacy PHA
Prescription Drug User Fee Act reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act.
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millennium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
Health Issues HCR
340B-related issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millennium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
Medicare/Medicaid MMM
Medicare coverage and reimbursement. H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millennium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.